Insider Trading March 27, 2026

Castellum Director Sells $21,129 in Stock as Company Posts Debt Retirement and Contract Gains

Director Charles Thomas McMillen reduces holdings while Castellum reports stronger liquidity and a major contract win via its subsidiary

By Nina Shah CTM
Castellum Director Sells $21,129 in Stock as Company Posts Debt Retirement and Contract Gains
CTM

Director Charles Thomas McMillen sold 30,000 shares of Castellum, Inc. (OTC:CTM) on March 25, 2026, for $21,129, according to a Form 4 filing. The transaction follows a recent share-price decline and leaves McMillen with 231,015 shares. Separately, the company has retired $400,000 of debt, increased cash to over $14 million, and its subsidiary Specialty Systems, Inc. secured a $49.8 million software support contract for the Naval Air Warfare Center Aircraft Division Lakehurst.

Key Points

  • Insider sale: Director Charles Thomas McMillen sold 30,000 shares on March 25, 2026, at $0.7043 per share for $21,129; he now directly owns 231,015 shares.
  • Balance sheet improvement: Castellum fully retired $400,000 of acquisition-era debt and reports having over $14 million in cash, versus more than $11 million in debt and $2 million in cash in July 2024.
  • Contract win: Specialty Systems, Inc., a Castellum subsidiary, secured a $49.8 million contract to provide software support for the Naval Air Warfare Center Aircraft Division Lakehurst - the third consecutive contract in this role.

A Form 4 filing with the Securities and Exchange Commission shows that Charles Thomas McMillen, a director of Castellum, Inc. (OTC:CTM), disposed of 30,000 shares of the company's common stock on March 25, 2026. The shares were sold at $0.7043 apiece, producing a total sale value of $21,129.

The sale occurred amid recent pressure on the stock. Over the prior week the share price had fallen 12.6%, and Castellum shares were trading at $0.62 at the time of the report - close to the 52-week low of $0.65. After completing the March 25 sale, McMillen directly holds 231,015 shares of Castellum common stock.

Market commentary referenced in the filing notes that certain valuation tools consider the stock undervalued at prevailing prices based on a Fair Value assessment. The referenced platform also provides a set of additional analytical suggestions for investors in CTM.


Beyond the insider transaction, Castellum has announced material improvements to its balance sheet and order flow. The company fully retired $400,000 of debt, which the company described as eliminating the remaining debt accrued during its acquisition phase. Following the debt retirement, Castellum reported having more than $14 million in cash on hand.

Those figures mark a notable shift from the company's position in July 2024, when it carried in excess of $11 million in debt and had approximately $2 million in cash. The change signals an improved liquidity profile relative to that prior period, based on the figures disclosed.

Operationally, Castellum's subsidiary Specialty Systems, Inc. (SSI) secured a $49.8 million contract to deliver software support services to the Naval Air Warfare Center Aircraft Division Lakehurst. This award represents the third consecutive contract that SSI has won to provide this support role.

In separate corporate news included in the filings, Canterra Minerals Corporation named Matt Manson to its board of directors. Manson is currently President and CEO of Radisson Mining Resources Inc. and brings more than 30 years of experience in the mining sector. His prior leadership roles have included positions guiding Marathon Gold Corporation through key project stages and serving as President and CEO of Stornoway Diamond Corporation.

The March 25 insider sale, the company's elimination of acquisition-related debt, the strengthened cash position, and the multi-year contract wins for SSI together present a mix of governance, financial and operational developments for investors monitoring Castellum and related small-cap issuers.

Risks

  • Share-price volatility: The stock fell 12.6% over the prior week and was trading near its 52-week low, indicating potential market sensitivity; this affects equity investors and small-cap market participants.
  • Concentration of improvements: While cash has increased and debt was retired, the company's recent liquidity and contract wins may still leave it exposed to execution and funding risks typical for smaller public companies.
  • Insider selling: The director's sale, while modest in dollar terms, may be interpreted by some market participants as a signal of reduced insider exposure, potentially influencing investor sentiment in the microcap and OTC markets.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026